Qian Yongbing, Xie Hui, Tian Rui, Lu Jian, Jin Wei, Wang Ruilan
Department of Critical Care Medicine, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, China. Corresponding author: Wang Ruilan, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Jul;29(7):581-585. doi: 10.3760/cma.j.issn.2095-4352.2017.07.002.
To analysis the immunological characteristics of patients with severe H1N1 influenza A, and to provide theoretical basis for predicting the prognosis of the disease.
A retrospective analysis was conducted. The clinical data of 15 patients diagnosed with severe H1N1 influenza A and admitted to Shanghai General Hospital of Nanjing Medical University from October 2015 to December 2016 were collected. All the patients were divided into survival and death groups according to 28-day survival. Clinical characteristics, treatment algorithm, organ function, inflammatory reaction and immune cell status were compared, and Cox regression was used to decide the risk factors of 28-day death in patients with severe H1N1 infection A.
All 15 patients with severe H1N1 infection A were enrolled, most of who presented with cough (93.3%), fever (86.7%), sputum production (80.0%), shortness of breath (73.3%), myalgia (40.0%) and fatigue (40.0%). All had been received anti-virus, antibiotics, mechanical ventilation and anti-coagulation therapy; some were treated with prone position, neuromuscular blocker and extracorporeal membrane oxygenation (ECMO). The incidences of acute myocardial and kidney injury were high, and the acute physiology and chronic health evaluation II (APACHE II) score (14.1±6.1) and sequential organ failure assessment (SOFA) score (9.6±4.1) implicated the critical condition. Of 15 patients, 4 patients died in 28 days, while 11 were cured and discharged. Compared with survival group, the patients in death group had higher levels of APACHE II score (22.7±3.8 vs. 11.8±3.8), troponin [cTn (μg/L): 0.52 (0.07, 2.02) vs. 0.15 (0.10, 0.45)] and blood urea nitrogen [BUN (mmol/L): 11.9 (6.7, 29.1) vs. 3.9 (2.7, 6.8)] and a lower level of blood platelets count [PLT (×10/L): 76±33 vs. 146±49, all P < 0.05]. The levels of C-reactive protein (CRP) and interleukin-6 (IL-6) within 24 hours of admission in death group were significantly higher than those of survival group [CRP (mg/L): 172.2±88.5 vs. 74.8±33.1, IL-6 (ng/L): 283.3 (140.1, 711.0) vs. 18.5 (12.7, 71.4), both P < 0.01]. Compared with survival group, the expressions of CD3, CD4, CD8 T cells and natural killer cell (NK cell) in death group were significantly decreased (CD3 T cell: 0.348±0.119 vs. 0.573±0.106, CD4 T cell: 0.135±0.046 vs. 0.344±0.098, CD8 T cell: 0.089±0.057 vs. 0.208±0.054, NK cell: 0.124±0.057 vs. 0.252±0.182, all P < 0.05), but there were no significant differences in CD4/CD8 ratio and human leucocyte antigen-DR positive (HLA-DR) T cell between death group and survival group (CD4/CD8 ratio: 1.57±0.26 vs. 1.83±0.54, HLA-DR T cell: 0.035±0.022 vs. 0.062±0.036, both P > 0.05). B lymphocyte in death group was significantly higher than that of survival group (0.477±0.136 vs. 0.229±0.121, P < 0.01). Cox regression analysis revealed that APACHE II score [risk ratio (RR) = 20.4, 95% confidence interval (95%CI) = 5.3-31.2, P = 0.017], CD4 T cell (RR = 11.1, 95%CI = 5.1-20.0, P = 0.048) and CD8 T cell (RR = 9.1, 95%CI = 4.3-16.7, P = 0.049) were independently risk factors of 28-day survival of patients with severe H1N1 influenza A.
Immunological paralysis and severe inflammatory response were early complicated with severe H1N1 influenza A, and these were significantly associated with prognosis.
分析甲型H1N1流感重症患者的免疫学特征,为预测该疾病的预后提供理论依据。
进行回顾性分析。收集2015年10月至2016年12月在南京医科大学附属上海第一人民医院确诊并收治的15例甲型H1N1流感重症患者的临床资料。根据28天生存情况将所有患者分为生存组和死亡组。比较两组患者的临床特征、治疗方案、器官功能、炎症反应及免疫细胞状态,并采用Cox回归分析确定甲型H1N1流感重症患者28天死亡的危险因素。
15例甲型H1N1流感重症患者均纳入研究,多数患者表现为咳嗽(93.3%)、发热(86.7%)、咳痰(80.0%)、气短(73.3%)、肌痛(40.0%)和乏力(40.0%)。所有患者均接受抗病毒、抗生素、机械通气及抗凝治疗;部分患者接受俯卧位通气、神经肌肉阻滞剂及体外膜肺氧合(ECMO)治疗。急性心肌损伤和急性肾损伤发生率较高,急性生理与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分(14.1±6.1)及序贯器官衰竭评估(SOFA)评分(9.6±4.1)提示病情危重。15例患者中,4例在28天内死亡,11例治愈出院。与生存组相比,死亡组患者APACHEⅡ评分(22.7±3.8比11.8±3.8)、肌钙蛋白[cTn(μg/L):0.52(0.07,2.02)比0.15(0.10,0.45)]和血尿素氮[BUN(mmol/L):11.9(6.7,29.1)比3.9(2.7,6.8)]水平更高,血小板计数[PLT(×10/L):76±33比146±49,均P<0.05]更低。死亡组患者入院24小时内C反应蛋白(CRP)和白细胞介素-6(IL-6)水平显著高于生存组[CRP(mg/L):172.2±88.5比74.8±33.1,IL-6(ng/L):283.3(140.1,711.0)比18.5(12.7,71.4),均P<0.01]。与生存组相比,死亡组CD3、CD4、CD8 T细胞及自然杀伤细胞(NK细胞)表达显著降低(CD3 T细胞:0.348±0.119比0.573±0.106,CD4 T细胞:0.135±0.046比0.344±0.098,CD8 T细胞:0.089±0.057比0.208±0.054,NK细胞:0.124±0.057比0.252±0.182,均P<0.05),但死亡组与生存组CD4/CD8比值及人类白细胞抗原-DR阳性(HLA-DR)T细胞差异无统计学意义(CD4/CD8比值:1.57±0.26比1.83±0.54,HLA-DR T细胞:0.035±0.022比0.062±0.036,均P>0.05)。死亡组B淋巴细胞显著高于生存组(0.477±0.136比0.229±0.121,P<0.01)。Cox回归分析显示,APACHEⅡ评分[风险比(RR)=20.4,95%置信区间(95%CI)=5.3-31.2,P=0.017]、CD4 T细胞(RR=11.1,95%CI=5.1-20.0,P=0.048)和CD8 T细胞(RR=9.1,95%CI=4.3-16.7,P=0.